NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $77,264 | -81.8% | 9,830 | -76.9% | 0.00% | -66.7% |
| Q2 2023 | $425,098 | +93.9% | 42,552 | +72.4% | 0.00% | +200.0% |
| Q1 2023 | $219,236 | -87.2% | 24,689 | -81.3% | 0.00% | -90.0% |
| Q3 2022 | $1,719,000 | +97.6% | 131,919 | +92.1% | 0.01% | +100.0% |
| Q2 2022 | $870,000 | +4.2% | 68,684 | +15.3% | 0.01% | -28.6% |
| Q1 2022 | $835,000 | +92.0% | 59,581 | +296.8% | 0.01% | +75.0% |
| Q4 2021 | $435,000 | +29.5% | 15,014 | +18.6% | 0.00% | 0.0% |
| Q2 2021 | $336,000 | +31.8% | 12,663 | +54.4% | 0.00% | +33.3% |
| Q1 2021 | $255,000 | – | 8,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |